Company research
Celcuity Inc.
CIK 1603454Updated Sep 26, 2026
SecurityCELC · NASDAQ · equity
Name history
Celcuity LLC · through Sep 15, 2017
CELC price & chart
Loading TradingView…
NASDAQ:CELC on TradingView ↗About the company
Celcuity is a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications. The company's first FDA-approved product is REVTORPYK (gedatolisib), a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- ABC, supported FDA approval of REVTORPYK for use in patients without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Results for the PIK3CA mutant cohort of VIKTORIA-1 have been released. VIKTORIA-2 is an ongoing Phase 3 clinical trial incorporating two independent studies, Study 1 and Study 2, in two separate cohorts of patients with ABC who are treatment-naive in the advanced setting. Study 1 is evaluating gedatolisib plus palbociclib plus fulvestrant as …
In the news
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC ↗
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
4 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
Show 5 more recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
4 filing
4 filing
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 466,558,000Source | 245,123,047Source | 191,219,398Source | 175,697,097Source |
| Property, Plant and Equipment, NetUSD | 499,000Source | 336,515Source | 228,782Source | 260,294Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 165,703,000Source | 22,514,823Source | 30,662,774Source | 24,571,557Source |
| Assets, CurrentUSD | 465,659,000Source | 244,571,030Source | 190,590,597Source | 175,190,537Source |
| Operating Lease, Right-of-Use AssetUSD | 51,000Source | 215,502Source | 400,019Source | 246,266Source |
| Other Assets, NoncurrentUSD | 349,000Source | — | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 366,003,000Source | 129,504,012Source | 51,450,076Source | 41,925,630Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | 318Source | 854Source | 1,121Source |
| Common Stock, Value, IssuedUSD | 48,000Source | 37,143Source | 25,506Source | 21,667Source |
| Additional Paid in CapitalUSD | 549,404,000Source | 387,436,682Source | 299,818,965Source | 230,045,566Source |
| Retained Earnings (Accumulated Deficit)USD | -448,897,000Source | -271,855,108Source | -160,076,003Source | -96,296,887Source |
| Stockholders' Equity Attributable to ParentUSD | 100,555,000Source | 115,619,035Source | 139,769,322Source | 133,771,467Source |
| Liabilities and EquityUSD | 466,558,000Source | 245,123,047Source | 191,219,398Source | 175,697,097Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 44,152,000Source | 31,722,907Source | 14,188,743Source | 6,881,554Source |
| Operating Lease, Liability, CurrentUSD | 54,000Source | 171,952Source | 184,950Source | 191,749Source |
| Accounts Payable, CurrentUSD | 6,407,000Source | 9,366,007Source | 5,076,699Source | 2,627,076Source |
| Operating Lease, Liability, NoncurrentUSD | — | 53,969Source | 225,922Source | 61,002Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | — | 22,184,948Source | 8,927,094Source | 4,060,280Source |
| Long-term DebtUSD | 137,547,000Source | 105,093,288Source | 37,565,660Source | 35,755,075Source |
| Short-term InvestmentsUSD | 275,794,000Source | 212,588,960Source | 149,919,974Source | 144,015,954Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 21,383,000Source | 6,988,341Source | 4,901,434Source | 4,638,205Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -3,040,000Source | 4,315,892Source | 2,430,614Source | 1,077,080Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -153,280,000Source | -83,466,743Source | -53,812,253Source | -36,008,171Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -64,084,000Source | -63,069,283Source | -5,008,207Source | -144,031,794Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 249,000Source | 249,878Source | 97,644Source | 158,768Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 360,552,000Source | 138,388,075Source | 64,911,677Source | 120,325,141Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 10,348,000Source | 7,586,084Source | 3,274,051Source | 1,255,280Source |
| Additional Financial Items | ||||
| Amortization of Debt Issuance Costs and DiscountsUSD | 3,137,000Source | 1,330,652Source | 241,752Source | 395,757Source |
| DepreciationUSD | 167,000Source | 129,947Source | 142,772Source | 210,918Source |
| General and Administrative ExpenseUSD | 27,197,000Source | 9,063,721Source | 5,636,326Source | 4,101,543Source |
| InterestExpenseNonoperatingUSD | 17,148,000Source | 10,280,445Source | — | — |
| Investment Income, InterestUSD | 12,298,000Source | 11,768,291Source | 7,777,602Source | 1,127,162Source |
| Net Income (Loss) Attributable to ParentUSD | -177,042,000Source | -111,779,105Source | -63,779,116Source | -40,370,040Source |
| Nonoperating Income (Expense)USD | -4,850,000Source | 1,487,846Source | — | — |
| Operating ExpensesUSD | 172,192,000Source | 113,266,951Source | 66,230,331Source | 39,391,091Source |
| Other Nonoperating Income (Expense)USD | — | — | 2,451,215Source | -978,949Source |
| Payments to Acquire InvestmentsUSD | 396,342,000Source | 705,164,950Source | 314,525,084Source | 143,873,026Source |
| Proceeds from Stock Options ExercisedUSD | 3,485,000Source | 769,571Source | 388,522Source | 152,412Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -172,192,000Source | -113,266,951Source | -66,230,331Source | -39,391,091Source |
| Other Nonoperating Income (Expense)USD | — | — | 2,451,215Source | -978,949Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -177,042,000Source | -111,779,105Source | -63,779,116Source | -40,370,040Source |
| Net Income (Loss) Attributable to ParentUSD | -177,042,000Source | -111,779,105Source | -63,779,116Source | -40,370,040Source |
| Earnings Per Share, BasicUSD per share | -3.79Source | -2.83Source | -2.69Source | -2.64Source |
| Earnings Per Share, DilutedUSD per share | -3.79Source | -2.83Source | -2.69Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 46,757,691Source | 39,449,393Source | 23,679,472Source | 15,418,543Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 46,757,691Source | 39,449,393Source | 23,679,472Source | — |
| Interest Expense (non-operating)USD | 17,148,000Source | 10,280,445Source | — | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 27,197,000Source | 9,063,721Source | 5,636,326Source | 4,101,543Source |
| Interest ExpenseUSD | — | — | 5,326,387Source | 2,106,111Source |
| Interest Expense, DebtUSD | 14,400,000Source | — | — | — |
| Investment Income, InterestUSD | 12,298,000Source | 11,768,291Source | 7,777,602Source | 1,127,162Source |
| Nonoperating Income (Expense)USD | -4,850,000Source | 1,487,846Source | — | — |
| Operating ExpensesUSD | 172,192,000Source | 113,266,951Source | 66,230,331Source | 39,391,091Source |
| Research and Development ExpenseUSD | 144,995,000Source | 104,203,230Source | 60,594,005Source | 35,289,548Source |
Filing attachments
celc-ex99_1.htm · 8-K · 2026-08-26
EX-99.1 2 celc-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer • If approved, REVTORPYK would be the first and only therapy for advanced breast cancer with a PIK3CA mutation that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 MINNEAPOLIS, August 26, 2026 - Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developi…
Read attachment ↗celc-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 celc-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update • REVTORPYK™ (gedatolisib) approved by the U.S. FDA for the treatment of HR+/HER2- PIK3CA Wild-Type locally advanced or metastatic breast cancer on July 14, 2026; on track for commercial launch late third quarter 2026 • NCCN® Clinical Practice Guidelines recommended REVTORPYK in combination with fulvestrant, with or without palbocicli…
Read attachment ↗ex99-1.htm · 8-K/A · 2026-07-15
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer REVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 In the Phase 3 VIKTORIA-1 trial, REVTORPYK combined with palbociclib and fulvestrant and REVTORPYK combined with fulvestrant reduced the risk of …
Read attachment ↗ex99-1.htm · 8-K · 2026-07-15
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer REVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 In the Phase 3 VIKTORIA-1 trial, REVTORPYK combined with palbociclib and fulvestrant and REVTORPYK combined with fulvestrant reduced the risk …
Read attachment ↗